Proximity Extension Assay (PEA) technology is the unique technology behind our Olink® Explore platform and Olink®
Target 96 and Target 48 panels. It enables high-throughput, multiplex
immunoassays of proteins using minimal volumes of serum, plasma, or
almost any other type of biological sample. Here we will show you how
our technology delivers this scale of multiplexing and sample throughput
without compromising on data quality or assay robustness.
Olink Proteomics provides world-class, scalable solutions for multiplexed protein biomarker discovery and protein analysis, based on a unique dual-recognition, DNA-coupled protein detection technology that provides unparalleled specificity with high sensitivity and broad dynamic range. The Olink library of thoroughly validated assays comprises ~3000 proteins that cover all major biological pathways and are available in a range of multiplexing levels and formats, from the Olink® Explore platform for high throughput biomarker discovery, to the disease/biological process-focused Olink® Target panels for targeted protein biomarker analysis. Backed by expert biostatistical and bioinformatic support, Olink's technology has been widely used across a broad range of applications in academic/clinical research and in drug development, with almost 1000 peer-reviewed articles published. Based in Uppsala, Sweden, the company is now a NASDAQ-listed organization with a strong global presence.